| Michael J Racenstein, MD | |
|
800 Biesterfield Rd, Elk Grove Village, IL 60007-3361 | |
| (847) 437-5500 | |
| (847) 952-7912 |
| Full Name | Michael J Racenstein |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 36 Years |
| Location | 800 Biesterfield Rd, Elk Grove Village, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154314912 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 036088554 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alexian Brothers Medical Center 1 | Elk grove village, IL | Hospital |
| St Alexius Medical Center | Hoffman estates, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elk Grove Imaging Associates Sc | 2961883459 | 12 |
News Archive
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a new tool to help surgeons use X-rays to track devices used in "minimally invasive" surgical procedures while also limiting the patient's exposure to radiation from the X-rays.
E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of an Op-Ed article from SmallcapInsights.com.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.
› Verified 3 days ago
| Entity Name | Decatur Radiology Physicians Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881640977 PECOS PAC ID: 1658353974 Enrollment ID: O20040602000158 |
News Archive
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a new tool to help surgeons use X-rays to track devices used in "minimally invasive" surgical procedures while also limiting the patient's exposure to radiation from the X-rays.
E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of an Op-Ed article from SmallcapInsights.com.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.
› Verified 3 days ago
| Entity Name | Elk Grove Radiology Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386730810 PECOS PAC ID: 9133169766 Enrollment ID: O20050503001144 |
News Archive
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a new tool to help surgeons use X-rays to track devices used in "minimally invasive" surgical procedures while also limiting the patient's exposure to radiation from the X-rays.
E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of an Op-Ed article from SmallcapInsights.com.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.
› Verified 3 days ago
| Entity Name | Radadvantage A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376719666 PECOS PAC ID: 2163597899 Enrollment ID: O20080814000765 |
News Archive
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a new tool to help surgeons use X-rays to track devices used in "minimally invasive" surgical procedures while also limiting the patient's exposure to radiation from the X-rays.
E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of an Op-Ed article from SmallcapInsights.com.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.
› Verified 3 days ago
| Entity Name | Thorek Radiology Group Nfp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588261978 PECOS PAC ID: 1658786421 Enrollment ID: O20210209002525 |
News Archive
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a new tool to help surgeons use X-rays to track devices used in "minimally invasive" surgical procedures while also limiting the patient's exposure to radiation from the X-rays.
E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of an Op-Ed article from SmallcapInsights.com.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.
› Verified 3 days ago
| Entity Name | Insight Chicago Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881261006 PECOS PAC ID: 2860894706 Enrollment ID: O20210714002059 |
News Archive
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a new tool to help surgeons use X-rays to track devices used in "minimally invasive" surgical procedures while also limiting the patient's exposure to radiation from the X-rays.
E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of an Op-Ed article from SmallcapInsights.com.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.
› Verified 3 days ago
| Entity Name | Elk Grove Imaging Associates Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497494033 PECOS PAC ID: 2961883459 Enrollment ID: O20220714002386 |
News Archive
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a new tool to help surgeons use X-rays to track devices used in "minimally invasive" surgical procedures while also limiting the patient's exposure to radiation from the X-rays.
E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of an Op-Ed article from SmallcapInsights.com.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael J Racenstein, MD 800 Biesterfield Rd, Elk Grove Village, IL 60007-3361 Ph: (847) 437-5500 | Michael J Racenstein, MD 800 Biesterfield Rd, Elk Grove Village, IL 60007-3361 Ph: (847) 437-5500 |
News Archive
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a new tool to help surgeons use X-rays to track devices used in "minimally invasive" surgical procedures while also limiting the patient's exposure to radiation from the X-rays.
E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of an Op-Ed article from SmallcapInsights.com.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.
› Verified 3 days ago
Westley Zimmer, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 800 Biesterfield Rd, Elk Grove Village, IL 60007 Phone: 312-942-5000 | |
Dr. Ross Alexander Ogilvie, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 800 Biesterfield Rd, Elk Grove Village, IL 60007 Phone: 847-437-5500 | |
Nilanjana Patel, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 31 Arlington Heights Road, Bright Light Radiology, Elk Grove Village, IL 60007 Phone: 847-439-2315 Fax: 847-439-3935 | |
Dr. Ernest John Laney Iv, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 31 S. Arlington Heights Road, Elk Grove Village, IL 60007 Phone: 847-439-2315 Fax: 847-439-3935 | |
Dr. Rajiv J Patel, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 800 Biesterfield Rd, Elk Grove Village, IL 60007 Phone: 847-981-5760 Fax: 847-956-5138 | |
Monica Owerczuk, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 31 Arlington Heights Road, Elk Grove Village, IL 60007 Phone: 847-439-2315 Fax: 847-439-3935 |